Dr. Reddy`s Laboratories announced the launch of the drug-free non-invasive migraine management wearable device Nerivio� in Germany through its step-down subsidiary betapharm. The launch marks the company`s entry into digital therapeutics in Europe. Nerivio� is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe. Nerivio� was presented in 2023 by Dr. Reddy`s at the DGN Kongress organised by the German Association of Neurology in Berlin, and the 17th European Headache Congress held in Barcelona, Spain. Dr. Reddy`s will present and launch Nerivio� during the Neurological Association of South Africa annual congress on April 17, 2024, in the presence of Dr. Stewart Tepper, Professor of Neurology at the Geisel School of Medicine - Dartmouth, and Vice President, New England Institute for Neurology and Headache. In May 2024, Nerivio� will also be presented at International Headache Society 2024 iHEAD meeting in Berlin, Germany. In subsequent months, Dr. Reddy`s will launch Nerivio� in Spain and the UK. Last year, Dr. Reddy`s entered into an exclusive agreement with Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, for the marketing and distribution of Nerivio� in multiple markets.Dr. Reddy`s launched Nerivio� in India in 2023. In India, Nerivio� is supported by Dr. Reddy`s unique patient support programme called `M-Free`. The programme is a comprehensive support system that enhances and streamlines the journey of the patients. M-Free includes services such as onboarding and counseling of patients, device demonstrations, doorstep delivery, flexible payment options, informative content, and dedicated customer care to help patients get the most out of the device. With lifestyle modification as a key recommendation for better management of migraine, M-Free awareness program offers a suite of value-add services such as nutritionist consultation, yoga and meditation sessions with certified specialists for holistic medicine free migraine management.Powered by Capital Market - Live News

Dr Reddys Laboratories and Bayer announced that both companies have entered into a partnership to market and distribute a second brand of Vericiguat in India. Under the terms of this agreement, Bayer has granted non-exclusive rights to Dr. Reddy`s under the brand name Gantra�. Vericiguat, a soluble guanylate cyclase (sGC) stimulator, in India, is indicated, along with guideline-based medical therapy, in adults with symptomatic chronic heart failure with reduced ejection fraction (less than 45%), following a recent event of worsening heart failure which required hospitalization or outpatient intravenous (IV) diuretics. Vericiguat works on a pathway not currently targeted by existing heart failure treatments and can reduce the combined risk of cardiovascular death and heart failure hospitalization in such patient . India has between 8-10 million people with heart failure, making it one of the largest populations with this condition. Powered by Capital Market - Live News

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 7 May 2024.Powered by Capital Market - Live News

Dr Reddys Laboratories has entered into a license agreement with Pharmazz, Inc. (Pharmazz), a U.S. based biopharmaceutical company developing and commercialising drug products to treat critically ill patients, to commercialise the first-in-class innovative drug Centhaquine in India. Developed by Pharmazz, Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by the Drugs Controller General of India (DCGI). As per the agreement, Dr Reddys has received exclusive rights to market and distribute Centhaquine in India. Pharmazz will be entitled to upfront payments and royalties. Dr. Reddy`s will market the product under the brand name Lyfaquin�, which it shall own. In addition to India, Dr. Reddy`s also receives marketing rights for Lyfaquin� from Pharmazz for Nepal. Powered by Capital Market - Live News

Dr. Reddy`s Laboratories announced the launch of Versavo� (bevacizumab) in the United Kingdom (UK). Dr. Reddy`s Versavo� is a (bevacizumab) biosimilar of Avastin�1 and indicated for the treatment of several types of cancers, including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer and metastatic breast cancer. Versavo� is the first Dr. Reddy`s biosimilar product to be approved and launched in the UK. It is available in strengths of 100mg and 400mg single use vials. Dr. Reddy`s launched Versavo� in India in 2019. Subsequently, Versavo� was introduced in other markets such as Thailand, Ukraine, Nepal, and Jamaica under the same brand name. In Colombia, the product was launched under the brand name Persivia�. Powered by Capital Market - Live News